Cariprazine is a Small Molecule owned by Gedeon Richter, and is involved in 62 clinical trials, of which 54 were completed, 7 are ongoing, and 1 is planned.

Cariprazine is a dopamine D3 receptor-preferring, D3/D2 dopamine receptor partial agonist antipsychotic drug candidate. The drug candidate is partial agonists that matched precisely the projected properties of the agonist-antagonist bifunctional compounds. It affects the way the brain works by interfering with communication among the brain's nerves. The D2 receptor is coupled to inhibitory G-proteins, which dissociate from the receptor on agonist binding and inhibit secondary messenger signaling mechanisms. Cariprazine is a serotonin 5-HT1A receptors agonist and antagonist activity at serotonin 5-HT2A receptors.

The revenue for Cariprazine is expected to reach a total of $31.2bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Cariprazine NPV Report.

Cariprazine is originated and owned by Gedeon Richter. Recordati and AbbVie are the other companies associated in development or marketing of Cariprazine.

Cariprazine Overview

Cariprazine (RGH -188, Vraylar, Reagila, Symvenu) is an atypical antipsychotic drug. It is formulated as hard gelatin capsules for oral route of administration. It is indicated for the treatment of manic or mixed episodes of bipolar 1 disorder and schizophrenia in adults. Vraylar is also indicated for the maintenance treatment of depressive episodes associated with bipolar I disorder (bipolar depression) in adults.

The drug candidate is also under development for the treatment of bipolar disorder, autism spectrum disorder and schizophrenia.

It was under development for the treatment of generalized anxiety disorder (GAD).

AbbVie Overview

AbbVie is a specialty biopharmaceutical company, which discovers, develops, manufactures, and commercializes drugs for the treatment of chronic and complex diseases. Its drugs are indicated for the treatment of metabolic diseases, rheumatological diseases, neurological disorders, viral diseases, skin diseases, complications associated with cystic fibrosis, pain related to endometriosis, diseases of the gastrointestinal tract, various types of cancer, and other serious health conditions. AbbVie is also advancing its pipeline programs for the treatment of cystic fibrosis, women’s health, various cancers, neurological disorders and other autoimmune diseases. The company markets its products directly to wholesalers, distributors, health care facilities, government agencies, specialty pharmacies and independent retailers through its own distribution centers and public warehouses worldwide. AbbVie is headquartered in North Chicago, Illinois, the US.

The company reported revenues of (US Dollars) US$56,197 million for the fiscal year ended December 2021 (FY2021), an increase of 22.7% over FY2020. In FY2021, the company’s operating margin was 31.9%, compared to an operating margin of 24.8% in FY2020. In FY2021, the company recorded a net margin of 20.5%, compared to a net margin of 10.1% in FY2020. The company reported revenues of US$14,812 million for the third quarter ended September 2022, an increase of 1.6% over the previous quarter.

Quick View – Cariprazine

Report Segments
  • Innovator (NME)
Drug Name
  • Cariprazine
Administration Pathway
  • Oral
Therapeutic Areas
  • Central Nervous System
Key Companies
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.